Foreign pharmaceutique representatives listening to a presentation at the RudaCure booth.
RudaCure set up a booth in the Rising Pavilion at 2025 Bio-Korea, recommended by KIT, and introduced the current status of développement de médicaments for TRPV1-related diseases.
Chinese and American companies expressed strong interest in the overseas rights for RCI001, which is actuellement in essais cliniques. For the vétérinaire traitement de la douleur actuellement under development, discussions on development stages and market were conducted through réunions de partenariat with a multinational pharmaceutique vétérinaire developer headquartered in the États-Unis.
The analgésique non narcotique development project attracted interest from investisseurs and major national entreprises pharmaceutiques, and RudaCure's booth was bustling with visitors throughout the event period.